LIGAND PHARMACEUTICALS INC (LGND): Entry into a Material Definitive Agreement
LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 d167360dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 LIGAND PHARMACEUTICALS INCORPORATED AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 25, 2026 0.00% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1
How this was made
The 30-second read
Why it matters
A new convertible debt instrument can shift valuation via (1) leverage/credit risk, (2) potential equity conversion/dilution, and (3) investor positioning in convertibles vs. common stock.
Market read
Traders may reassess LGND’s capital structure and near-term dilution/convertible overhang based on the disclosed convertible notes framework and issuance size cap.
What to watch
Key missing details (net proceeds, conversion price, call/put features, and whether this is a new issuance vs. documentation of prior terms) could materially change dilution/valuation impact.
Background
The 8-K references an indenture dated June 25, 2026 between Ligand Pharmaceuticals and U.S. Bank Trust Company as trustee for 0.00% Convertible Senior Notes due 2031.
Ticker impact
Ligand Pharmaceuticals entered a material definitive agreement for 0.00% convertible senior notes due 2031, per its June 25, 2026 8-K.
Near-term price reaction is likely muted-to-moderate, with focus on deal size ($700m cap) and conversion/dilution terms rather than operations.
This is a primary SEC 8-K disclosure of a financing instrument (convertible notes). The excerpt provides the issuance cap and instrument type, but not pricing, conversion rate, or proceeds, limiting precision on equity impact.
Market effects
Convertible financings can signal funding needs or balance-sheet optimization within biotech/pharma tools, but no sector-wide read-across is provided here.
Primarily US-listed credit/equity sentiment; limited regional spillover indicated by the filing excerpt.
No explicit global counterparties or cross-border terms are disclosed in the provided text.
Counterpoint
The notes are 0.00% coupon convertibles, which may be structured to reduce cash interest burden; equity dilution may be less immediate than feared.
Key entities
- issuerLigand Pharmaceuticals Incorporated
Company entering the material definitive agreement/indenture for 0.00% convertible senior notes due 2031.
- trusteeU.S. Bank Trust Company, National Association
Trustee named in the convertible notes indenture.
